Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Bank of America
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) was downgraded by research analysts at Bank of America from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. They currently have a $3.00 target price on the stock. Bank of America‘s price target suggests a potential […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) was downgraded by research analysts at Bank of America from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. They currently have a $3.00 target price on the stock. Bank of America‘s price target suggests a potential […]
